Search results for " beta-2"

showing 10 items of 67 documents

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study

2016

Rüdiger Sauer,1 Michaela Hänsel,2 Roland Buhl,3 Roman A Rubin,4 Marcel Frey,5 Thomas Glaab2,3 1Lung Centre Ulm, Ulm, Germany; 2Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 3Pulmonary Department, Mainz University Hospital, Mainz, Germany; 4Pulmonary Specialist Practice, Wiesbaden, Germany; 5Biometrics, Alcedis GmbH, Gießen, Germany Background: Maintaining and improving physical functioning is key to mitigating the cycle of deconditioning associated with chronic obstructive pulmonary disease (COPD). We evaluated the impact of free combination of the long-acting anticholinergic tiotropium plus the long-acting β2-agonist ol…

Malereal-worldTime FactorsnoninterventionalHealth StatusSeverity of Illness IndexCholinergic AntagonistsPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicinetiotropiumDeconditioningPhysical functioningSurveys and QuestionnairesProspective Studies030212 general & internal medicineLungOriginal ResearchCOPDOlodaterolGeneral MedicineTiotropium bromideMiddle AgedBronchodilator AgentsDrug CombinationsTreatment OutcomeFemalemedicine.drugmedicine.medical_specialtymedicine.drug_classInternational Journal of Chronic Obstructive Pulmonary Diseasechronic obstructive pulmonary disease03 medical and health sciencesAdministration InhalationSeverity of illnessmedicineAnticholinergicphysical functioningHumansTiotropium BromideIntensive care medicineAdrenergic beta-2 Receptor AgonistsAgedolodaterolbusiness.industryNebulizers and VaporizersRecovery of Functionmedicine.diseaseBenzoxazines030228 respiratory systemchemistryPhysical therapyObservational studybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Binding Sites for Neurotoxins and Cholinergic Ligands in Peripheral and Neuronal Nicotinic Receptors Studies with Synthetic Receptor Sequencesa

1995

Molecular Sequence DataNeurotoxinsIn Vitro TechniquesReceptors NicotinicLigandsBinding CompetitiveGeneral Biochemistry Genetics and Molecular BiologyStructure-Activity RelationshipGanglion type nicotinic receptorSpecies SpecificityHistory and Philosophy of ScienceConsensus SequenceEnzyme-linked receptorAnimalsAmino Acid SequenceBinding siteReceptorNeuronsBinding SitesSequence Homology Amino AcidChemistryGeneral NeuroscienceAntibodies MonoclonalPeripheralCell biologyNicotinic agonistCholinergicAlpha-4 beta-2 nicotinic receptorPeptidesSequence AlignmentAnnals of the New York Academy of Sciences
researchProduct

Mapping of a binding site for ATP within the extracellular region of the Torpedo nicotinic acetylcholine receptor beta-subunit.

1997

Using 2,8,5'-[H-3]ATP as a direct photoaffinity label for membrane-bound nicotinic acetylcholine receptor (nAChR) from Torpedo marmorata, we have identified a binding site for ATP in the extracellular region of the beta-subunit of the receptor. Photolabeling was completely inhibited in the presence of saturating concentrations of nonradioactive ATP, whereas neither the purinoreceptor antagonists suramin, theophyllin, and caffeine nor the nAChR antagonists alpha-bungarotoxin and d-tubocurarine affected the labeling reaction. Competitive and noncompetitive nicotinic agonists and Ca2+ increased the yield of the photoreaction by up to 50%, suggesting that the respective binding sites are allost…

Molecular Sequence DataPhotoaffinity LabelsReceptors NicotinicTorpedoTritiumBiochemistryPeptide Mappingchemistry.chemical_compoundGanglion type nicotinic receptorAdenosine TriphosphateAdenine nucleotideAnimalsChymotrypsinTrypsinAmino Acid SequenceBinding siteBinding SitesbiologyHydrolysisCell MembranePeptide FragmentsNicotinic acetylcholine receptorNicotinic agonistBiochemistrychemistrybiology.proteinAlpha-4 beta-2 nicotinic receptorExtracellular SpaceAdenosine triphosphateSequence AnalysisATP synthase alpha/beta subunitsBiochemistry
researchProduct

Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease.

2000

Abstract One of the most prominent cholinergic deficit in Alzheimer’s disease (AD) is the reduced number of nicotinic acetylcholine receptors (nAChR) in the hippocampus and cortex of AD patients, as compared to age-matched controls. This deficit results in reduced nicotinic cholinergic excitation which may not only impair postsynaptic depolarization but also presynaptic neurotransmitter release and Ca 2+ -dependent intracellular signaling, including transcriptional activity. Presently, the most common approach to correct the nicotinic cholinergic deficit in AD is the application of cholinesterase inhibitors. Due to the resulting increase in synaptic acetylcholine levels, both in concentrati…

NeuronsPatch-Clamp TechniquesBiologyNeurotransmissionReceptors NicotinicSynaptic TransmissionCell LineBehavioral NeuroscienceNicotinic acetylcholine receptorMiceGanglion type nicotinic receptorNicotinic agonistAllosteric RegulationAlzheimer DiseaseMuscarinic acetylcholine receptormedicineAnimalsHumansNicotinic AgonistsAlpha-4 beta-2 nicotinic receptorNeuroscienceAcetylcholine5-HT receptorAllosteric Sitemedicine.drugBehavioural brain research
researchProduct

Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting beta2-agonists on asthma pathophysiology: a review of…

2004

Chronic inflammation and smooth muscle dysfunction are consistent features of asthma, and are responsible for disease progression and airway remodelling. The development of chronic airway inflammation depends upon the recruitment and activation of inflammatory cells and the subsequent release of inflammatory mediators, including cytokines. Cellular and histological evaluation of drugs with anti-inflammatory activity, such as inhaled corticosteroids (ICSs), is achieved by analysing samples of lung tissue or biological fluids, obtained by techniques such as bronchial biopsy, bronchoalveolar lavage and sputum induction. These provide valuable information on the inflammatory processes occurring…

Pathophysiology of asthmamedicine.drug_classInflammationAdrenal Cortex HormonesBronchodilatorAdministration InhalationmedicineHumansPharmacology (medical)Adrenergic beta-2 Receptor AgonistsAsthmaLungmedicine.diagnostic_testLeukotriene receptorbusiness.industryNebulizers and Vaporizersmedicine.diseaseAsthmarespiratory tract diseasesmedicine.anatomical_structureBronchoalveolar lavageDelayed-Action PreparationsImmunologyLeukotriene AntagonistsBronchoconstrictionDrug Therapy CombinationReceptors Adrenergic beta-2medicine.symptombusinessDrugs
researchProduct

Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants

2014

Acute bronchiolitis is the leading cause of lower respiratory t ract infection and hospitalization in children less than 1y ear of age worldwide. It is usually a mild disease, but some children may develop severe symptoms, requiring hospital admission and ventilatory support in the ICU. Infants with pre-existing risk factors (prematurity, bronchopulmonary dysplasia, congenital heart diseases and immunodeficiency) may be predisposed to a severe form of the disease. Clinical diagnosis of bronchiolitis is manly based on medical history and physical examination (rhinorrhea, cough, crackles, wheezing and signs of respiratory distress). Etiological diagnosis, with antigen or genome detection to i…

PediatricsBronchiolitis; Bronchopulmonary dysplasia; Congenital heart diseases; Immunodeficiency; Oxygen therapy; Prematurity; Prevention; Prophylaxis; Respiratory syncytial virus;ReviewRespiratory syncytial virusSeverity of Illness IndexCongenital heart diseasesSettore MED/38 - Pediatria Generale E SpecialisticaAdrenergic beta-2 Receptor AntagonistsVitamin DChildrenRespiratory distressVitaminsEnvironmental exposurePatient DischargeAnti-Bacterial AgentsBronchodilator AgentsHospitalizationSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICABronchiolitisbronchiolitisPrematuritymedicine.drugPalivizumabRespiratory Therapymedicine.medical_specialtyEpinephrineDecision MakingAntibodies Monoclonal HumanizedAntiviral AgentsIntensive Care Units NeonatalBronchiolitis Respiratory syncytial virus Prematurity Bronchopulmonary dysplasia Congenital heart diseases Immunodeficiency Oxygen therapy Prevention ProphylaxismedicineHumansImmunodeficiencyAcute bronchiolitisMedical historyConsensus DocumentIntensive care medicineGlucocorticoidsPalivizumabAsthmaSaline Solution HypertonicPrimary Health CareProphylaxisbusiness.industryNebulizers and VaporizersPreventionInfant NewbornOxygen Inhalation TherapyHumidityEnvironmental ExposureAcute bronchiolitis Consensus Documentmedicine.diseaseBronchopulmonary dysplasiaOxygen therapyHypertonic salineBronchopulmonary dysplasiaBronchiolitisbusinessItalian Journal of Pediatrics
researchProduct

Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study.

2015

Background: Pregnant women with asthma need to take medication during pregnancy.Objective: We sought to identify whether there is an increased risk of specific congenital anomalies after exposure to antiasthma medication in the first trimester of pregnancy.Methods: We performed a population-based case-malformed control study testing signals identified in a literature review. Odds ratios (ORs) of exposure to the main groups of asthma medication were calculated for each of the 10 signal anomalies compared with registrations with nonchromosomal, nonsignal anomalies as control registrations. In addition, exploratory analyses were done for each nonsignal anomaly. The data set included 76,249 reg…

PediatricsINFANTSAdrenal Cortex HormonesPregnancyOdds RatioImmunology and AllergyAnti-Asthmatic AgentsPOPULATIONAsthma medicationTetralogy of FallotMATERNAL ASTHMAeducation.field_of_studyOUTCOMESWOMEN3. Good healthPREVALENCEEuropeAnesthesiaPrenatal Exposure Delayed Effectsinhaled β2-agonistsFemalemedicine.drugRiskmedicine.medical_specialty1ST TRIMESTERfirst trimester exposurePopulationImmunologyUNITED-STATESCongenital AbnormalitiesAsthma medication ; congenital anomalies ; first trimester exposure ; inhaled corticosteroids ; inhaled β(2)-agonists ; pregnancy.:Medisinske Fag: 700 [VDP]medicineHumansMALFORMATIONSeducationAdrenergic beta-2 Receptor AgonistsMETAANALYSISAsthmaPregnancySpina bifidaGastroschisisbusiness.industrycongenital anomaliesOdds ratiomedicine.diseaseAsthmainhaled beta(2)-agonistsPregnancy Trimester FirstCase-Control StudiesSalbutamolinhaled corticosteroidsbusinessThe Journal of allergy and clinical immunology
researchProduct

Murine embryonic stem cell line CGR8 expresses all subtypes of muscarinic receptors and multiple nicotinic receptor subunits: Down-regulation of α4- …

2015

Non-neuronal acetylcholine mediates its cellular effects via stimulation of the G-protein-coupled muscarinic receptors and the ligand-gated ion channel nicotinic receptors. The murine embryonic stem cell line CGR8 synthesizes and releases non-neuronal acetylcholine. In the present study a systematic investigation of the expression of nicotinic receptor subunits and muscarinic receptors was performed, when the stem cells were grown in the presence or absence of LIF, as the latter condition induces early differentiation. CGR8 cells expressed multiple nicotinic receptor subtypes (α3, α4, α7, α9, α10, β1, β2, β3, β4, γ, δ, e) and muscarinic receptors (M1, M3, M4, M5); M2 was detected only in 2 …

PharmacologyImmunologyMuscarinic acetylcholine receptor M3Down-RegulationMuscarinic acetylcholine receptor M2Cell DifferentiationMuscarinic acetylcholine receptor M1BiologyReceptors NicotinicReceptors MuscarinicCell biologyCell LineMiceProtein SubunitsNicotinic agonistGanglion type nicotinic receptorGene Expression RegulationMuscarinic acetylcholine receptor M5Muscarinic acetylcholine receptorImmunology and AllergyAnimalsAlpha-4 beta-2 nicotinic receptorEmbryonic Stem CellsInternational immunopharmacology
researchProduct

Expression and renaturation of the N-terminal extracellular domain of torpedo nicotinic acetylcholine receptor alpha-subunit.

1998

The N-terminal extracellular region (amino acids 1-209) of the alpha-subunit of the nicotinic acetylcholine receptor (nAChR) from Torpedo marmorata electric tissue was expressed as inclusion bodies in Escherichia coli using the pET 3a vector. Employing a novel protocol of unfolding and refolding, in the absence of detergent, a water-soluble globular protein of 25 kDa was obtained displaying approximately 15% alpha-helical and 45% beta-structure. The fragment bound alpha-[3H]bungarotoxin in 1:1 stoichiometry with a KD value of 0.5 nM as determined from kinetic measurements (4 nM from equilibrium binding). The kinetics of association of toxin and fragment were of second order, with a similar …

Protein DenaturationProtein FoldingMolecular Sequence DataReceptors NicotinicTorpedoBiochemistrylaw.inventionchemistry.chemical_compoundGanglion type nicotinic receptorlawExtracellularmedicineEscherichia coliAnimalsAmino Acid SequenceCloning MolecularMolecular BiologyMethyllycaconitineCell BiologyBungarotoxinBungarotoxinsRecombinant ProteinsNicotinic acetylcholine receptorBiochemistrychemistryAlpha-4 beta-2 nicotinic receptorTorpedoAcetylcholinemedicine.drugProtein BindingThe Journal of biological chemistry
researchProduct

Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT)study follow-up

2019

Abstract Background Chronic obstructive pulmonary disease (COPD) is characterised by recurring exacerbations. We estimated the costs of healthcare resources for COPD management funded by the Italian National Healthcare Service (INHS) for one year. Methods We examined the demographic, clinical, and economic variables at enrolment and follow-up visits (at 6 and 12 months) of COPD patients participating in the SAT study and referred to 20 Italian pulmonary centres with different institutional characteristics. Costs were expressed in Euro (€) 2018. A random effects log-linear panel regression model was performed to predict the average cost per patient. Results Most of the centres were public in…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCost-Benefit AnalysisSocio-culturaleMuscarinic AntagonistsPersonal SatisfactionSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineHealth careMedicineHumansCOPD management Econometric model Healthcare costs030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAverage costAgedAged 80 and overCOPDbiologyCOPD management; Econometric model; Healthcare costsbusiness.industryCOPD managementOxygen Inhalation TherapyRegression analysisHealth Care CostsLamaMiddle AgedHealthcare costsbiology.organism_classificationmedicine.diseaseRandom effects modelBronchodilator AgentsPatient Care ManagementRespiratory Function TestsEconometric model030228 respiratory systemItalyEmergency medicinePublic universityDisease ProgressionPatient ComplianceDrug Therapy CombinationbusinessPanel dataFollow-Up Studies
researchProduct